New PET scan may sharpen bladder cancer staging
NCT ID NCT04018053
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This early-phase study tests a special PET scan agent (18F-fluciclovine) to see if it can more accurately show how far muscle-invasive bladder cancer has spread compared to standard CT or MRI scans. Sixteen adults with bladder cancer scheduled for bladder removal surgery will receive the PET scan beforehand. The goal is to compare scan results with what surgeons find during the operation, helping improve future cancer staging.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.